Exalief (eslicarbazepine acetate)
- Region
- 🇪🇺 EU
- Active substance
- eslicarbazepine acetate
- Company
- BIAL - Portela Ca, S.A.
- Status
- Lapsed
- Therapeutic area
- Epilepsy
- EU approval
- Tue 21 Apr 2009
- Application
- EMEA/H/C/000987
- ATC
- N03AF04
- Official record
- www.ema.europa.eu
Indication
Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zebinix Authorised · BIAL - Portela & Ca, S.A.
Follow Exalief
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.